Síndrome de Sneddon
Revisado por Dr Philippa Vincent, MRCGPÚltima actualización por Dr Colin Tidy, MRCGPÚltima actualización 18 Aug 2023
Cumple con las directrices editoriales
- DescargarDescargar
- Compartir
- Language
- Discusión
- Versión en audio
- Agregar a fuentes preferidas en Google
Profesionales Médicos
Los artículos de Referencia Profesional están diseñados para ser utilizados por profesionales de la salud. Están escritos por médicos del Reino Unido y se basan en evidencia de investigación, así como en guías del Reino Unido y Europa. Puede encontrar uno de nuestros artículos de salud más útil.
Synonym: Ehrmann-Sneddon syndrome
What is Sneddon's syndrome?
Sneddon's syndrome is a non-inflammatory arteriopathy in which livedo reticularis is associated with cerebrovascular disease.1 It is slowly progressive and may go undiagnosed for some time.2 It may be seen in patients with an autoimmune disorder - eg, síndrome antifosfolípido o lupus eritematoso sistémico (LES).
How common is Sneddon's syndrome? (Epidemiology)
It has been estimated that the incidence is 4 per 1 million per annum and generally occurs in women between the ages of 20 and 42 years.3
Although initially thought to have a genetic aetiology (one family cluster displayed autosomal dominant inheritance), further studies have failed to demonstrate any family history in most affected patients.1
Sneddon's syndrome symptoms (Presentation)3
Sneddon's syndrome develops slowly over a variable timeframe.
Livedo reticularis may precede the onset of stroke by years and the trunk and/or buttocks are involved in nearly all patients. The cerebrovascular manifestations are mostly secondary to ischaemia (transient ischemic attacks y cerebral infarction).
Other neurological symptoms range from headache, cerebral haemorrhage, seizures, as well as cognitive and psychiatric disturbances.
Involvement of fundi, peripheral nerves, heart, and kidneys is frequent but usually asymptomatic.
Livedo reticularis is a bluish mottling of skin, usually on the legs, and the appearance may be aggravated by exposure to cold.4
Enfermedades asociadas
Sneddon's syndrome has been classified as primary if there is no clear cause, or secondary where it occurs as part of an autoimmune disorder (eg, poliarteritis nodosa, LES, síndrome antifosfolípido), or in a thrombophilic state (eg, thrombocythaemia).5 6
Other associations include hypertension, systemic ischaemia (including ischaemic heart disease), heart valve lesions and venous thrombosis.
Investigaciones
Antiphospholipid antibodies have been found in 80% of patients with Sneddon's syndrome.7
Neuroimaging, including MRI, histological, immunohistochemical and ultrasound evaluation may be useful for diagnosis.8
Histological findings of skin biopsies are characteristic and the involved vessels are small to medium-sized arteries at the border of dermis.3
Sneddon's syndrome treatment and management9
The optimal management remains uncertain. Long-term anticoagulation has been recommended for cerebral ischaemic events.3
In patients without any prior history of thromboembolism, minimise risk factors (stop smoking and/or combined oral contraceptives, control any hypertension, and treat any hyperlipidaemia).
Consider prophylaxis with low-dose aspirin (clopidogrel if unable to take aspirin), particularly in patients with antiphospholipid or antiprothrombin antibodies. It may be appropriate for all patients but more research is needed.
Patients with a history of thrombosis are treated indefinitely with anticoagulation (with warfarin ± low-dose aspirin).
Immunosuppressive agents are used in some cases chronically resistant to anticoagulation treatment.
Pronóstico
Some symptoms tend to resolve over a very variable time course.
Prevention of further vascular events with anticoagulation is the key to a good prognosis.
Actualizaciones exclusivas para profesionales de la salud
Mantente informado con las últimas actualizaciones clínicas, perspectivas profesionales y orientación basada en evidencia. El boletín de Patient Pro selecciona contenido esencial para profesionales de la salud, entregado directamente en tu bandeja de entrada.
Al suscribirte aceptas nuestros Política de Privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.
Lecturas adicionales y referencias
- Silawy A, Odeh M, Borissovsky N, et al; Sneddon's syndrome. Isr Med Assoc J. 2020 Oct;22(10):657.
- Andrea G, Emma S, Anna B, et al; Sneddon Syndrome. Neurol India. 2022 Nov-Dec;70(6):2465-2466. doi: 10.4103/0028-3886.364083.
- Elmahi H, Mernissi FZ; Sneddon syndrome. Pan Afr Med J. 2019 Sep 4;34:9. doi: 10.11604/pamj.2019.34.9.11903. eCollection 2019.
- Sneddon Syndrome; Herencia Mendeliana en Línea en el Hombre (OMIM)
- Marinho JL, Piovesan EJ, Leite Neto MP, et al; Clinical, neurovascular and neuropathological features in Sneddon's syndrome. Arq Neuropsiquiatr. 2007 Jun;65(2B):390-5.
- Wu S, Xu Z, Liang H; Sneddon's syndrome: a comprehensive review of the literature. Orphanet J Rare Dis. 2014 Dec 31;9:215. doi: 10.1186/s13023-014-0215-4.
- Livedo Reticularis; DermIS (Sistema de Información de Dermatología)
- Sayin R, Bilgili SG, Karadag AS, et al; Sneddon syndrome associated with Protein S deficiency. Indian J Dermatol Venereol Leprol. 2012 May-Jun;78(3):407. doi: 10.4103/0378-6323.95483.
- Dutra LA, Braga-Neto P, Pedroso JL, et al; Sneddon's syndrome: case report and review of its relationship with antiphospholipid syndrome. Einstein (Sao Paulo). 2012 Apr-Jun;10(2):230-2.
- Song HB, Woo SJ, Jung CK, et al; Acute central retinal artery occlusion associated with livedoid vasculopathy: a variant of Sneddon's syndrome. Korean J Ophthalmol. 2013 Oct;27(5):376-80. doi: 10.3341/kjo.2013.27.5.376. Epub 2013 Sep 10.
- Lewandowska E, Wierzba-Bobrowicz T, Wagner T, et al; Sneddon's syndrome as a disorder of small arteries with endothelial cells proliferation: ultrastructural and neuroimaging study. Folia Neuropathol. 2005;43(4):345-54. Folia Neuropathol. 2005;43(4):345-54.
- Seok HH, Noh Y, Jeong EC, et al; Treatment of Refractory Lower Extremity Ulcer Associated with Sneddon's Syndrome. Arch Plast Surg. 2013 May;40(3):277-80. doi: 10.5999/aps.2013.40.3.277. Epub 2013 May 16.
Acerca del revisorVer biografía completa

Dra. Philippa Vincent, MRCGP
Médico General, Autor Médico
MB BS, Bsc, MRCGP (2000), DCH, DFSRH, DRCOG
Dra Philippa Vincent es un médico de cabecera del NHS que trabaja en el norte de Londres.
Historial del artículo
Artículo también disponible en Inglés, Alemán, Español, Francés, Italiano, Portugués, Hindi, Hebreo, Árabe, y Sueco.
Siguiente revisión prevista: 16 de agosto de 2028
18 Aug 2023 | Última versión

Pregunta, comparte, conecta.
Navega por discusiones, haz preguntas y comparte experiencias en cientos de temas de salud.

¿Te sientes mal?
Evalúa tus síntomas en línea de forma gratuita
Más en enfermedades multisistémicas
- Albinismo
- Amiloidosis
- Enfermedad de Behçet
- Síndrome de Chediak-Higashi
- Granulomatosis eosinofílica con poliangeítis
- Enfermedad injerto contra huésped
- Granuloma anular
- Granulomatosis con poliangeítis
- Hamartomas
- Púrpura de Henoch-Schönlein
- Síndrome de hipermovilidad
- Enfermedad de Kawasaki
- Multimorbilidad
- Encefalomielitis miálgica
- Miositis - polimiositis y dermatomiositis
- Poliarteritis nodosa
- Retinitis pigmentosa
- Artritis seronegativas
- Lupus eritematoso sistémico
- Arteritis de Takayasu
